Press Releases
Connect Biopharmaceuticals to Present at the 25th Annual Future Leaders in Biotech Industry on March 23, 2018, in New York City

Taicang, Suzhou, China, Feb. 24, 2018 -  Connect Biopharmaceuticals, today announced that Dr. Zheng Wei, the company's co-founder and Chief Executive Officer, will present an update on the company’s clinical programs and drug discovery platform at the 25th Annual Future Leaders in Biotech Industry conference organized by BioCentury, on Friday, March 23, at 9 a.m. EST.  The conference will take place at the Millennium Broadway Hotel & Conference Center.

 

About Connect Biopharmaceuticals.

 

Connect Biopharmaceuticals is a China-based global clinical-stage company focused on discovery and development of novel immune modulators for the treatment of autoimmune diseases and inflammation. Our drug discovery technology platform is built on the biology of T cell functions, which identifies molecules that target clinically-validated disease pathways.

 

Our leading drug candidate is CBP-307, an orally-active, next-generation S1P1 and S1P5 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases.  We have completed a Phase 1b randomized, double-blind, placebo-controlled study that assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-307. CBP-307 exhibited an excellent safety profile and potent T cell modulation activity as well as optimal pharmacokinetic and pharmacodynamic profiles, demonstrating best-in-class potential. CBP-307 is entering Phase 2 studies of ulcerative colitis and Crohn’s disease in H1, 2018. Our second drug candidate is CBP-201, an antibody that targets IL-4Rα and blocks a central pathway in allergic inflammation, and will be studied for the treatment of atopic dermatitis, asthma, and other inflammatory condition. CBP-201 is expected to enter Phase 1 clinical study in the first quarter of 2018.  Additional programs included CBP-174, CBP-233, and CBP-312.





TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower